In the FXR Ligand OCA in NASH Treatment (FLINT) trial, OCA induced NASH remission in 22% of patients, whereas placebo induced NASH remission in 13% of patients [157]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.